Total Body Irradiation Treatments for Patients Treated at European Institute of Oncology
1 other identifier
observational
50
1 country
1
Brief Summary
Patients eligible undergoing total body irradiation as candidates for bone marrow or peripheral stem cell transplant.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Feb 2018
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 22, 2018
CompletedFirst Submitted
Initial submission to the registry
March 22, 2024
CompletedFirst Posted
Study publicly available on registry
March 28, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2024
CompletedMarch 28, 2024
March 1, 2024
6.9 years
March 22, 2024
March 27, 2024
Conditions
Outcome Measures
Primary Outcomes (2)
Overall Survival
Number of patients death
5 years
Disease free survival
Number of oncological event (local recurrence, distant metastasis, other primary tumor)
5 years
Study Arms (1)
Total Body Irradiation (TBI)
Patients treated at European Institute of Oncology with Total Body Irradiation (TBI)
Eligibility Criteria
Patients treated at European Institute of Oncology with Total Body Irradiation (TBI)
You may qualify if:
- Patients undergoing total body irradiation as candidates for bone marrow or peripheral stem cell transplantation.
- Signed informed consent
You may not qualify if:
- Patients who do not undergo total body irradiation
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
European Institute of Oncology
Milan, Italy
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Barbara Alicja Jereczek
European Institute of Oncology
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 22, 2024
First Posted
March 28, 2024
Study Start
February 22, 2018
Primary Completion
December 31, 2024
Study Completion
December 31, 2024
Last Updated
March 28, 2024
Record last verified: 2024-03